



Providing Choice & Value

Generic CT and MRI Contrast Agents



**FRESENIUS
KABI**

CONTACT REP

AJNR

**The Role of AVM Microsurgery in the
Aftermath of A Randomized Trial of
Unruptured Brain Arteriovenous
Malformations**

M.T. Lawton

This information is current as
of July 23, 2025.

AJNR Am J Neuroradiol 2015, 36 (4) 617-619

doi: <https://doi.org/10.3174/ajnr.A4193>

<http://www.ajnr.org/content/36/4/617>

\$100,000 per patient when last estimated 15 years ago, plus additional costs for potential treatment complications.¹³

Although intervention after hemorrhage often shows little worsening and sometimes improvement, ARUBA documents the difficulties in achieving lesion eradication without some disturbance in perilesional brain function for those previously asymptomatic. While we await new studies, the need for interventional management for those who have bled should justify studying elements of bAVMs that predict hemorrhage. The ARUBA data can be read as a challenge to the justification of interventions in those who have not bled.

ACKNOWLEDGMENTS

This work was supported in part from a gift from Vital Projects Fund Inc, New York, New York.

Disclosures: J.P. Mohr—*RELATED: Grant: NINDS (U01 NS051483).** Christian Stapf—*RELATED: Grant: NIH/NINDS.** Andreas Hartmann—*RELATED: Grant: NIH (U01 NS051483).** John Pile-Spellman—*UNRELATED: Expert Testimony: against a doctor who published and treated a patient who subsequently died, with an unruptured Spetzler-Martin grade 4 AVM; the doctor documented in the chart that he told the family the patient had a grade 2.* Helen Kim—*RELATED: Grant: NIH.** *Comments: for patient enrollment into the ARUBA trial (money received directly and by institution).* *Money paid to the institution.

REFERENCES

1. Ondra SL, Troupp H, George ED, et al. **The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment.** *J Neurosurg* 1990;73:387–91
2. A Randomized Trial of Unruptured Brain AVMs (ARUBA). <http://clinicaltrials.gov/ct/show/NCT00389181>. Accessed March 23, 2006
3. Mohr JP, Parides MK, Stapf C, et al. **Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.** *Lancet* 2014;383:614–21
4. Cockroft KM, Jayaraman MV, Amin-Hanjani S, et al. **A perfect storm: how a randomized trial of unruptured brain arteriovenous malformations' (ARUBA's) trial design challenges notions of external validity.** *Stroke* 2012;43:1979–81
5. Bambakidis NC, Cockroft K, Connolly ES, et al. **Preliminary results of the ARUBA study.** *Neurosurgery* 2013;73:E379–81
6. Mocco J, O'Kelly C, Arthur A, et al. **Randomized clinical trials: the double edged sword.** *J Neurointerv Surg* 2013;5:387–90
7. Mohr JP, Parides M, Moquete E, et al. **Spetzler-Martin Grade and outcomes by randomization assignment in the ARUBA trial (abstract).** *Stroke* 2014;45:A160
8. Kim H, Al-Shahi Salman R, McCulloch CE, et al. **Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors.** *Neurology* 2014;83:590–97
9. Parides MK, Overbey JR, Stapf C, et al. **Projecting longer term results in the ARUBA trial.** In: *Proceedings of the 23rd European Stroke Meeting*, Nice, France. May 6–9, 2014:97
10. van Beijnum J, van der Worp HB, Buis DR, et al. **Treatment of brain arteriovenous malformations: a systematic review and meta-analysis.** *JAMA* 2011;306:2011–19
11. Stieg PE, Janardhan V, Riina HA. **Multimodality therapy: treatment algorithms.** In: Stieg PE, Batjer HH, Samson D, eds. *Intracranial Arteriovenous Malformations*. New York: Informa Healthcare; 2006: 135–43
12. Knopman J, Stieg PE. **Management of unruptured brain arteriovenous malformations.** *Lancet* 2014;383:581–83
13. Berman MF, Hartmann A, Mast H, et al. **Determinants of resource**

utilization in the treatment of brain arteriovenous malformations. *AJNR Am J Neuroradiol* 1999;20:2004–08

EDITORIAL

The Role of AVM Microsurgery in the Aftermath of A Randomized Trial of Unruptured Brain Arteriovenous Malformations

M.T. Lawton

Microsurgical resection is the first-line therapy or criterion standard for many brain arteriovenous malformations because of its high cure rate, low complication rate, and immediacy. Surgical results have improved with time with the following: 1) the creation of grading systems to select patients likely to experience optimal outcomes; 2) the development of instruments like bipolar forceps and AVM microclips that coagulate or occlude feeding arteries effectively; 3) the recognition of AVM subtypes that help decipher AVM anatomy; and 4) the refinement of surgical approaches, strategies, and dissection techniques that facilitate safe AVM resection.^{1–3} This impressive evolution of AVM surgery is at odds with the finding of A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) that medical management alone was superior to interventional therapy for the prevention of death or stroke in patients with unruptured AVMs followed for 33 months.⁴

An important explanation for the ARUBA finding is the surprisingly nonsurgical management of patients in the interventional group in the trial. Overall, 81% of patients were treated with embolization alone (32%), radiosurgery alone (33%), or combined embolization and radiosurgery (16%), and only 17 patients (18%) were treated surgically, with or without embolization. Therefore, the 3-fold increase in death or stroke in the interventional arm reflects current nonsurgical therapies and should not be interpreted as an indictment of AVM surgery. In the aftermath of ARUBA, it is important to clarify the safety, efficacy, and outcomes associated with AVM resection.

Our experience in managing 232 Spetzler-Martin grade I and II AVMs, the most favorable AVMs for surgery and the ones most likely to have been selected for treatment outside the randomization process of ARUBA, exemplifies a surgical posture toward low-grade AVMs that regards curative resection as the first-line or criterion standard therapy for most lesions.⁵ We used embolization as a preoperative adjunct and reserved radiosurgery for risky AVMs in deep, inaccessible locations; in eloquent areas that might be associated with postoperative neurologic deficits; and/or with diffuse nidus morphology that might complicate microdissection. Patients were carefully selected to optimize outcomes, with a mean age of 38 years, Lawton-Young grades of ≤III in 69% of

<http://dx.doi.org/10.3174/ajnr.A4193>

patients, and few (<4%) AVMs in deep locations or the brain stem. Conservative embolization minimized additional treatment risk, with only 43% of patients undergoing embolization and no patients experiencing endovascular complications. Surgical cures were confirmed in all patients who underwent postoperative angiography. Overall, 6 patients (3%) were worse neurologically after surgery, with 161 patients (78%) in total and 91 patients (91%) with unruptured AVMs experiencing good outcomes (modified Rankin Scale scores, 0–1). These surgical results are consistent with other reports in the literature. In a review of 1235 patients with low-grade AVMs, the average surgical morbidity and mortality rates were 2.2% and 0.3%, respectively, with an average cure rate of 98.5% and a postoperative or delayed hemorrhage rate of 0.3%.⁵

The management of AVMs in other parts of the world is diverging from the surgical approach described above. In Europe, for example, treatment is often limited to only ruptured AVMs, beginning with aggressive embolization, frequently adding radiosurgery for incompletely embolized AVMs, and rarely resorting to surgical resection. Onyx (Covidien, Irvine, California) is an important endovascular advancement over N-butyl 2-cyanoacrylate glue and has improved the efficacy of endovascular therapy, but cure rates are still low and curative attempts are associated with increased complications, occlusion of critical draining veins, and adverse imaging findings in as many as 40% of patients. In a review of 1297 patients with mostly low-grade AVMs, the average endovascular morbidity and mortality rates were 6.2% and 1.6%, respectively, with an average cure rate of 29% and a postoperative or delayed hemorrhage rate of 8.0%.⁵ Therefore, aggressive endovascular therapy has higher procedural risks, substantially lower cure rates, and increased hemorrhage risks compared with surgery.

A similar comparison can be made with radiosurgery for low-grade AVMs. Although these lesions are ideal for radiosurgery because of their lower target volumes and higher obliteration rates, the 2- to 3-year latency period between treatment and obliteration opens a time window for AVM hemorrhage and associated complications. Radiation-induced complications are low, but in a review of 1051 patients with low-grade AVMs, 7.2% of patients hemorrhaged after treatment, resulting in morbidity and mortality rates of 6.5% and 1.2%, respectively.⁵ The 75.2% radiosurgical cure rate was substantially better than the endovascular cure rate, but still less than that of surgery. Therefore, despite the technologic advances in endovascular and radiosurgical therapy, surgery still offers the best cure rate, lowest risk profile, and greatest protection against hemorrhage for low-grade AVMs. Surgery cannot compete with the minimally invasive appeal of these other modalities, but this issue remains secondary to functional outcome.

How do we interpret the ARUBA findings in this context? First, on the basis of the surgical experience described above, a substantial number of neurosurgical investigators in ARUBA did not consider AVMs with low Spetzler-Martin grades (low treatment risk) to be in equipoise with medical management (high hemorrhage risk) and “selected treatment outside of the randomization process”⁴ (177 patients, or close to the number of included patients). Conversely, intermediate (31.8%) and high-grade

AVMs (10.3%) that are generally considered to have a more benign natural history and high risk for any treatment were included in the trial, diminishing the interventional results.

Second, with its unusual bias toward nonsurgical therapy and no data published on cure rates, the number of incompletely obliterated AVMs was likely high and resulted in ongoing ruptures. Therefore, the event rates observed in Kaplan-Meier estimates of “as-treated” patients reflected the procedural morbidity of interventional therapies plus the delayed morbidity of latency hemorrhages associated with radiosurgery and incomplete embolization. The outcome of such a group could never exceed that of an observational group whose only morbidity was the natural history risk.

Third, the shortage of surgical expertise in the ARUBA trial is apparent. Two-thirds of patients in the interventional group had low-grade, surgical AVMs; yet, only 18% underwent surgery, which is well below the expectation for the criterion standard therapy. The rates of stroke and death in this trial do not match the reported surgical outcomes. Therefore, the management of AVMs in ARUBA reflects a nonsurgical posture consistent with the fact that 38 of the 65 ARUBA sites were in Europe, Australia, and Brazil. Centers were required to manage 10 patients with AVMs per year, but there were no minimum requirements for neurosurgeons. AVM resection is among the most challenging neurosurgical cases, and the best AVM surgeons typically perform more than 25 resections annually. Had the ARUBA trial been embraced by the neurosurgical community, the application of surgical therapy would have been higher, the interventional outcomes would have been better, and the benefits of intervention would have been apparent. Had ARUBA been more surgical with complete resections and no delayed hemorrhages in incompletely treated patients, the event rates observed in Kaplan-Meier estimates of “as-treated” patients would have plateaued and the benefits of intervention would have been realized in much fewer than 10 years.

These critiques were validated in an analysis of our ARUBA-eligible patients managed outside the trial. As a participating ARUBA site, the University of California, San Francisco, screened 473 patients for eligibility, enrolled 4 patients, and had complete data on 74 eligible patients managed outside the trial, of whom half had low-grade AVMs. Forty-three patients (71% of treated patients) were treated surgically with or without preoperative embolization, 15 patients (25% of treated patients) were treated radiosurgically, and 13 patients (18% of the overall cohort) were observed. The risk of stroke and death and the degree of clinical impairment among treated patients were lower than those in ARUBA, with primary outcome rates of 11%, 27%, and 8% for surgery, radiosurgery, and observation, respectively. The 3-fold difference in primary outcome reported in ARUBA disappeared with a different management strategy and a different surgical expertise, leaving no significant difference in the rate of stroke or death between treated and observed patients (hazard ratio, 1.34; 95% CI, 0.12–14.53; $P = .807$).⁶ Therefore, our results in ARUBA-eligible patients managed outside that trial led to an entirely different conclusion about AVM intervention, due to the primary role of surgery, judicious surgical selection with estab-

lished outcome predictors, and technical expertise developed at a high-volume AVM center.

These critiques beg for another trial to re-establish the role of surgery in AVM management, this time conducted and embraced by the neurosurgical community: *Beyond ARUBA: Randomized Low-Grade Brain AVM study*, Observation versus Surgery (BARBADOS). Effort is ongoing to organize, fund, and initiate it. There is now urgency among neurosurgeons to respond to ARUBA, which we expect to increase acceptance of such a trial. In the meantime, the management of ruptured AVMs should remain unaffected by ARUBA and surgery should be regarded as the first-line or criterion standard therapy for most low-grade AVMs, with conservative embolization as a preoperative adjunct. High surgical cure rates and excellent functional outcomes in patients with both ruptured and unruptured AVMs support a dominant surgical posture, with radiosurgery reserved for risky AVMs in deep, inaccessible, and highly eloquent locations.

REFERENCES

1. Spetzler RF, Martin NA. **A proposed grading system for arteriovenous malformations.** *J Neurosurg* 1986;65:476–83
2. Lawton MT, Kim H, McCulloch CE, et al. **A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery.** *Neurosurgery* 2010;66:702–13; discussion 713
3. Lawton MT. *Seven AVMs: Tenets and Techniques for Resection.* New York: Thieme Medical Publishers; 2014
4. Mohr JP, Parides MK, Stapf C, et al. **Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.** *Lancet* 2014;383:614–21
5. Potts MB, Lau D, Abula AA, et al; UCSF Brain AVM Study Project. **Current surgical results with low-grade brain arteriovenous malformations.** *J Neurosurg* 2015 Feb 6. [Epub ahead of print]
6. Rutledge WC, Abula AA, Nelson J, et al. **Treatment and outcomes of ARUBA-eligible patients with unruptured brain arteriovenous malformations at a single institution.** *Neurosurg Focus* 2014;37:E8

EDITORIAL

A Randomized Trial of Unruptured Brain Arteriovenous Malformations Study: What Impact on Clinical Care and Therapeutic Decision?

C. Cognard

One hundred nine patients presenting with an unruptured AVM have been recruited in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) in the no-treatment arm and have been followed up for 33.7 months (306.1 patient years).¹ Eight hemorrhages (2.6% annual bleed rate) and 4 ischemic strokes (1.3%) occurred, bringing the annual stroke risk to 3.9%. ARUBA confirmed what we already knew—that is, leaving an AVM untreated brings a high lifetime stroke risk.

According to the New York Islands AVM Study,^{2,3} there are 3 identified factors associated with an increased risk of rupture of an AVM (previous rupture, deep venous drainage, deep location), leading to a reported annual risk from 0.9% to 32%. Some other factors such as arterial/nidal aneurysms and venous stenosis or dilations are considered to increase the annual risk of bleeding, even if there are no good estimates of their respective impacts.

Interventional treatments have been developed in the past decades to select patients presenting with an unruptured AVM; but in the absence of exhaustive data on the comparative risks of treatment/no treatment, the decision to offer treatment or observation lies entirely on the individual center and physician running the risk of intervention or rather the risk of rupture without treatment. Even more contingency-dependent, a patient with an unruptured AVM is offered the option of surgery, endovascular embolization, radiosurgery, or a combination of these 3 options, depending on the level of skill, experience, or mere availability of a trained operator.

Despite a plethora of single-center or multicenter reports in the literature, the methodology is rather weak and nothing could support the drafting of guidelines for this very difficult therapeutic decision.

The only piece of evidence useful to this purpose is a randomized controlled trial comparing the different options, ideally featuring a large number of patients, a long follow-up, a precise clinical end point, and an analysis of the influence of the risk factors of natural history and different treatments.

The objective of such a trial would be to define the option with the longest deficit-free survival stratified for AVM characteristics.

Randomized controlled trials (RCTs) are particularly adapted to homogeneous diseases. As an example, coronary stenosis is ideal for randomization: The disease appears homogeneous for the sake of screening, the study sample is very large, and the time of observation is short, with an expected outcome at short term. The interventional procedure is well-established and standardized across centers.

Brain AVMs are not ideal subjects for RCTs. The disease is rare and extremely heterogeneous (age, AVM size, location, eloquence, depth, architecture, and flow dynamics, just to mention a few variables), and therapeutic options can vary among centers and among physicians in the same centers on the basis of their experience and their level of technology expertise.

Designing an RCT that could compare multiple treatment options in such a heterogeneous disease is definitely a challenge, one that ARUBA could not handle but that we still need to take.

To give a patient the highest chance of deficit-free survival, the operator should be able to do the following:

- 1) Identify factors of increased bleeding risk
- 2) Identify factors of the increased interventional treatment risk
- 3) Compare the risk of death and handicap in the long term of an untreated AVM with the risk of performing an intervention (also evaluating the option of complete or incomplete occlusion of the AVM).

To answer these questions, we have 2 options: either running an RCT that looks at a limited study population (eg, no treatment versus surgery in superficial small AVMs in a noneloquent area or no treatment versus radiosurgery in deeply located deep venous